Synaptiq Therapeutics Launches with Acquisition of Clinical-Stage SYN-001 Program

SYN-001Positive

AI Analysis

Summary

Synaptiq Therapeutics was formed to acquire the clinical-stage SYN-001 program from Nobias Therapeutics, an FDA-designated orphan and rare pediatric disease therapeutic candidate. A Phase IIb trial is planned to further evaluate SYN-001 for treating neuropsychiatric symptoms associated with 22q11.2 Deletion Syndrome.

Clinical Trial Data

Phase

IIb

Outcome Details

Synaptiq Therapeutics formed to acquire SYN-001 clinical-stage program from Nobias Therapeutics

Importance:5/10

Sentiment:

0.60

acquisitionorphan drugrare pediatric diseaseFDA designationPhase IIbneuropsychiatric22q11.2 Deletion Syndrome

Read the original article

Published by PR Newswire Pharma on July 23, 2026 12:51 PM

Read Original